Latest News

CellmAbs awarded by the European Commission

CellmAbs was selected and awarded with funding by the European Commission, through the SME Innovation Associate program. This European program aims to support innovative, high-potential Enterprises that demonstrate specialized skills in the development of groundbreaking technologies that create a positive impact while driving economic growth.

NOVA Impact Stories: CellmAbs and SARS-CoV-2

CellmAbs is a NOVA Spin-off that is using its knowledge and exploring ways of leveraging its innovative cancer therapies in the fight against COVID-19.

An innovative approach to Cancer

When treating epithelial cancers, conventional treatments often affect normal tissues and fail to eliminate highly aggressive cancer cells responsible for the disease spreading and relapse. Several tumor biomarkers have been identified as potential targets, leading to the development of more effective therapies that can significantly improve clinical outcomes while reducing toxicity.

The advent of antibody-based therapies for Cancer has created a new paradigm in the oncology landscape. In fact, antibodies can target tumor cells with high specificity and, when bound to cancer cells, antibodies can activate a number of mechanisms that can induce the immune system to kill tumor cells.

CellmAbs is developing monoclonal antibodies and adoptive T cell therapies as well as diagnostic devices for early detection of Cancer in patients.

Translational R&D: a success case

CellmAbs is a spin-off company of NOVA University and is a success case of translational research. CellmAbs technology is the outcome of years of research conducted in collaboration with Porto Institute of Oncology (IPO Porto) and HZDR in Germany.